

Hatsun Agro Product Limited
 Registered Office: "DOMAINE"
 # 1/20A, Rajiv Gandhi Salai (DMR), Karapakkam, Chennai - 600 097.
 Tel: (91-44) 2450 1622 Fax: (91-44) 2450 1422
 CIN: L15499TN1986PLCO12747 Website: www.hap.in

NOTICE FOR LOSS OF SHARE CERTIFICATE
 The following share certificates of the Company have been reported lost/misplaced and the holders of the said share certificates have requested the Company for issue of Duplicate Share Certificates. Notice is hereby given that the Company will proceed to issue Duplicate Share Certificates to the below mentioned persons unless a valid objection is received by the Company within 15 days from the date of publication of this notice.

SL-NO	FOLIO-NO	CERT.NO.	NO.OF SHARES	DISTINCTIV NO. FROM	DISTINCTIVE TO	NAME OF THE SHAREHOLDER
1	10147	382	2000	68816517	68818516	KANDASWAMY S
2	11429	2069	500	106701400	106701899	NAGARAJ S
3	10287	1339	2000	71101515	71103514	D THANGAMANI
	10287	2602	1000	107512209	107513208	D THANGAMANI
4	11846	1373	2000	71301015	71303014	V TAMIL SELVI
	11846	2635	1000	107611459	107612458	V TAMIL SELVI
5	10857	1905	500	106288449	106288948	H KRISHNAN
6	10587	2346	500	107224658	107225157	RUKMINI DEVI K
7	10587	3304	600	151927540	151928139	RUKMINI DEVI K
8	11477	73	1000	68099933	68099932	AVANI SHARMA
	11477	1565	500	1051407284	105971706	AVANI SHARMA
	11477	2814	600	151407284	151407883	AVANI SHARMA

Any person(s) having objections to the issue of the duplicate share certificates should lodge his/her/their objection with all supporting documents with the Company at its Registered Office within 15 days from the appearance of this notice failing which the Company will proceed to issue Duplicate Share Certificate(s) to the persons mentioned above and thereafter no objection to the issue of duplicate share Certificates will be entertained from any person(s).

Place : Chennai
 Date : 12-02-2020

For Hatsun Agro Product Limited
 Sd/-
 G.Somasundaram
 Company Secretary

TULSYAN NEC LIMITED
 Regd. Off. : 1st Floor, Apex Plaza, 3, Nungambakkam High Road, Chennai - 600 034. Phone : 044 - 6199 1060.
 Fax : 044 - 6199 1066. email : investor@tulsyanec.in
 Website : www.tulsyanec.in CIN No. : L28920TN1947PLC007437

Extract of Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine Months ended December 31, 2019 under Ind AS

Sl. No.	Particulars	Standalone			Consolidated		
		Quarter ended December 31, 2019 (Unaudited)	Year to date figures December 31, 2019 (Unaudited)	Year to date figures December 31, 2018 (Unaudited)	Quarter ended December 31, 2019 (Unaudited)	Year to date figures December 31, 2019 (Unaudited)	Year to date figures December 31, 2018 (Unaudited)
1.	Total Income from Operations	17,345.38	55,906.53	61,949.48	17,480.22	57,253.16	61,872.91
2.	Net Profit/(Loss) for the period (before tax and exceptional items)	(4,596.03)	(13,787.68)	(21,280.00)	(4,589.13)	(13,281.67)	(20,801.43)
3.	Net Profit/(Loss) for the period before tax (after exceptional items)	(4,596.03)	(13,787.68)	(21,280.00)	(4,589.13)	(13,281.67)	(20,801.43)
4.	Net Profit/(Loss) for the period after tax (after exceptional items)	(4,596.03)	(13,787.68)	(21,280.00)	(4,589.13)	(13,281.67)	(20,801.43)
5.	Other comprehensive income (net of tax)	4.65	13.95	57.06	4.65	13.95	57.06
6.	Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other comprehensive income (after tax))	(4,591.38)	(13,773.73)	(21,222.94)	(4,584.48)	(13,267.72)	(20,744.37)
7.	Equity Share Capital (face Value of Rs. 10 per share)	1,471.38	1,471.38	1,471.38	1,471.38	1,471.38	1,471.38
8.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year						
9.	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)						
	(a) Basic	(31.24)	(93.71)	(144.63)	(31.19)	(90.27)	(141.37)
	(b) Diluted	(31.24)	(93.71)	(144.63)	(31.19)	(90.27)	(141.37)

NOTES:
 1. The above results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board Of Directors at their meeting held on February 14, 2020
 2. The statement has been prepared in accordance with the companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
 3. The above is an extract of the detailed format of the unaudited financial results for the quarter and nine months ended December 31, 2019 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Obligations Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results for the Quarter and Nine months ended December 31, 2019 are available on the website of the BSE Limited i.e. www.bseindia.com, on the Stock Exchange where the Company's shares are listed and on the website of the Company i.e. www.tulsyanec.in
 4. The previous year figures have been regrouped/re-classified wherever necessary.

for Tulsyan NEC Limited
 Sd/-
 Sanjay Tulsyan
 Managing Director
 DIN : 00632802

Sd/-
 Lalit Kumar Tulsyan
 Executive Chairman
 DIN : 00632823

Place : Chennai
 Date : 14th February, 2020

Apollo Hospitals Enterprise Limited
 Corporate Identity Number : L85110TN1979PLC008035
 Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
 Tel. +91-44-28290956, Fax.+91-44-28290956
 Email: investor.relations@apollohospitals.com, Website : www.apollohospitals.com

Extract of Statement of Unaudited Financial Results for the Three and Nine Months Ended December 31, 2019
 (Rs. in Lakhs, except per share data)

Particulars	Standalone						Consolidated					
	Three months ended 31/12/2019 Unaudited	Preceding Three months ended 30/09/2019 Unaudited	Corresponding Three months ended 31/12/2018 Unaudited	Year to date figures for current period ended 31/12/2019 Unaudited	Year to date figures for previous period ended 31/12/2018 Unaudited	Previous year ended 31/03/2019 Audited	Three months ended 31/12/2019 Unaudited	Preceding Three months ended 30/09/2019 Unaudited	Corresponding Three months ended 31/12/2018 Note 3	Year to date figures for current period ended 31/12/2019 Unaudited	Year to date figures for previous period ended 31/12/2018 Note 3	Previous year ended 31/03/2019 Audited
Total Income from Operations (net)	2,53,251	2,46,752	2,17,715	7,23,397	6,17,964	8,34,890	2,92,140	2,84,424	2,50,753	8,34,739	7,13,762	9,64,888
Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	14,564	14,035	13,040	40,680	34,248	46,247	14,530	13,365	10,301	37,335	26,162	37,353
Net Profit/(Loss) for the period (before Tax, after Exceptional and/or Extraordinary Items)	14,564	14,035	13,040	40,680	34,248	46,247	14,530	13,365	10,301	37,335	26,162	37,353
Net profit/(Loss) for the period after tax (after Exceptional and Extraordinary Items)	9,475	9,060	8,693	26,465	22,609	30,276	8,995	8,310	4,987	22,220	12,734	20,016
Total Comprehensive Income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	9,395	9,029	8,285	26,489	20,238	27,364	8,900	7,762	4,916	21,716	10,303	17,104
Paid up Equity Share Capital (Face value of Rs.5/- each)	6,956	6,956	6,956	6,956	6,956	6,956	6,956	6,956	6,956	6,956	6,956	6,956
Other Equity						381384						
Earnings Per Share of Rs. 5/- each												
Basic	+6.81	+6.51	+6.25	+19.02	+16.25	21.76	+6.62	+6.20	+4.10	+16.93	+11.10	16.97
Diluted	+6.81	+6.51	+6.25	+19.02	+16.25	21.76	+6.62	+6.20	+4.10	+16.93	+11.10	16.97

* Not Annualised

Notes
 1. The above is an extract of the detailed format of financial results (both standalone and consolidated) for the three and nine months ended December 31, 2019 filed with stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the stock exchange websites www.nseindia.com and www.bseindia.com and also the company's website www.apollohospitals.com.
 2. The unaudited standalone and consolidated financial results of Apollo Hospitals Enterprise Limited ("the Company") for the three and nine months ended December 31, 2019 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on February 12 and February 13, 2020 respectively and have been subjected to limited review by the statutory auditors.
 3. The consolidated results for the three months and nine months ended December 31, 2018 are approved by the Company's Board of Directors but have not been subjected to limited review by the statutory auditors.
 4. The Board of Directors in their meeting held on February 13, 2020 have declared an interim dividend @6% i.e., Rs.3.25 (Rupees Three and Twenty Five paise) per equity share of Rs.5 (Rupees Five only) each, for the financial year ending 31st March, 2020. The Company has fixed Wednesday, 26th February, 2020 as the Record Date for the purpose of payment of Interim Dividend and the same will be paid on or before 5th March, 2020.
 5. The listed non-convertible debentures of the Company aggregating to Rs.50,000 lakhs as on December 31, 2019 are secured by way of first charge on the Company's properties and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures
 6. The Board of Directors at their meeting held on November 14, 2018 had approved a Scheme of Arrangement ("the Scheme") between Apollo Hospitals Enterprise Limited ("AHEL") and Apollo Pharmacies Limited ("APL") segment to APL by way of slump sale, subject to necessary approvals by stock exchanges, shareholders, National Company Law Tribunal and all other requisite regulatory authorities. The Company received no objection letters from National Stock Exchange of India Limited and BSE Limited. Further, the Company obtained approvals from Competition Commission of India (CCI) and from the equity shareholders in October 2019. The Scheme would become effective upon filing of the Scheme, as sanctioned by the NCLT, with the Registrar of Companies.
 7. The Board of Directors of the Company had approved the sale of investments in an associate, Apollo Munich Health Insurance Company Limited (AMHI) to Housing Development Finance Corporation Limited subject to meeting closing conditions, which includes obtaining regulatory approvals from Insurance Regulatory and Development Authority of India (IRDA), Competition Commission of India (CCI) and National Housing Bank (NHB). The approval from IRDA was received on January 1, 2020 and the closing conditions were met on January 9, 2020.
 8. The Board of Directors in their meeting held on February 13, 2020, approved the proposal of merger of following subsidiary companies with the Company.
 a. Apollo Home Healthcare (India) Limited and
 b. Western Hospitals Corporation Private Limited
 9. Standalone :-
 Effective April 1, 2019, the Company adopted Ind AS 116 "Leases", applied to all lease contracts existing as on the said date, using the modified retrospective method. Under this method, the cumulative effect of initial application is recognised in retained earnings at April 1, 2019.
 On transition to Ind AS 116, the Company recognised right-of-use assets amounting to Rs. 120,539 lakhs (net of related accumulated depreciation), lease liabilities amounting to Rs. 141,926 lakhs and Rs. 24,193 lakhs (debit) in retained earnings (net of deferred tax) as at April 1, 2019. The Company has discounted lease payments using the applicable incremental borrowing rate as at April 1, 2019 for measuring the lease liability. During the three and nine months ended December 31, 2019, the Company has recognized interest expense on lease liabilities amounting to Rs. 3,224 lakhs & Rs. 9,449 lakhs and depreciation on right-of-use asset amounting to Rs. 3,914 lakhs and Rs. 11,158 lakhs respectively. The effect of applying this standard resulted in reduction of profit by Rs. 1,415 lakhs and Rs. 4,085 lakhs for the three and nine months ended December 31, 2019, respectively.
 Consolidated:-
 Effective April 1, 2019, the Group adopted Ind AS 116 "Leases", applied to lease contracts existing as on the said date, using the modified retrospective method, except for two lease arrangements for which the modified prospective approach has been used. Under the modified retrospective method, the cumulative effect of initial application is recognised in retained earnings at April 1, 2019.
 On transition to Ind AS 116, the Group recognised right-of-use assets amounting to Rs. 159,208 lakhs (net of related accumulated depreciation), lease liabilities amounting to Rs. 190,524 lakhs and Rs. 30,546 lakhs in retained earnings (net of deferred tax) as at April 1, 2019. The Group has discounted lease payments using the applicable incremental borrowing rate as at April 1, 2019 for measuring the lease liability. During the three and nine months ended December 31, 2019, the Group has recognized interest expense on lease liabilities amounting to Rs. 4,274 lakhs and Rs. 12,604 lakhs and depreciation on right-of-use asset amounting to Rs. 5,099 lakhs and Rs. 14,682 lakhs respectively. The effect of applying this standard resulted in reduction of profit by Rs. 1,884 lakhs and Rs. 5,483 lakhs for the three months and nine months ended December 31, 2019.

Place : Chennai
 Date : 13th February 2020

for APOLLO HOSPITALS ENTERPRISE LIMITED
 DR. PRATHAP C REDDY
 Executive Chairman